BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) following mixed Q3 results and 2016 guidance reset.Nachman ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook NegativeNovember 8, 2016 2:14 PM Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'November 8, 2016 10:35 AM Valeant Pharma (VRX) Sees Solid Bounce Off Morning LowsNovember 8, 2016 10:16 AM Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's RaffatNovember 8, 2016 10:03 AM FDA Posts Valeant Pharma (VRX) Warning Letter Related to Rochester PlantNovember 8, 2016 9:33 AM Valeant Pharma (VRX) says ex-CEO Pearson is still consulting in 'limited' capacity - Conf. callNovember 8, 2016 8:57 AM Valeant Pharma (VRX) Sinks 27% in Pre-Open Trade, Falling Below $14November 8, 2016 8:56 AM Valeant (VRX) Misses, Lowers, Delays - Wells Fargo's MarisNovember 8, 2016 8:33 AM Valeant (VRX) Miss and Guide Down Expected, But Magnitude Maybe Not - MizuhoNovember 8, 2016 8:25 AM Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI RaffatNovember 8, 2016 7:53 AM Valeant Pharma (VRX) Misses Q3 EPS by 20c, Cuts FY16 OutlookNovember 8, 2016 6:02 AM Valeant Reports Third Quarter 2016 Financial ResultsNovember 8, 2016 6:00 AM